A61K39/39591 - page 4 - CPC Classification Index

#901

20140234230

2014-08-21

Stomatological composition

#902

20140227250

2014-08-14

STABLE FORMULATIONS OF ANTIBODIES TO TSLP

#903

20140199729

2014-07-17

Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof

#904

20140199303

2014-07-17

Stable liquid formulation of etanercept

#905

20140193359

2014-07-10

Stable compositions of high-concentration allotype-selected antibodies for small-volume administration

#906

20140186373

2014-07-03

Anti-BAFFR antibody formulations

#907

20140178401

2014-06-26

Anti-IL-23 antibodies

#908

20140178383

2014-06-26

Stable formulations of polypeptides and uses thereof

#909

20140178294

2014-06-26

Ultrafiltration concentration of allotype selected antibodies for small-volume administration

#910

20140161815

2014-06-12

CELL CULTURE METHODS TO REDUCE ACIDIC SPECIES

#911

20140134172

2014-05-15

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

#912

20140127227

2014-05-08

Protein formulations containing amino acids

#913

20140127222

2014-05-08

Formulation of human antibodies for treating TNF-α associated disorders

#914

20140127219

2014-05-08

Antibodies for treatment of cancer

#915

20140113355

2014-04-24

Process for obtaining an IgG composition through heat treatment

#916

20140105909

2014-04-17

Sclerostin antibody crystals and formulations thereof

#917

20140099697

2014-04-10

Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide

#918

20140099301

2014-04-10

Antibody formulation

#919

20140086931

2014-03-27

Formulation of human antibodies for treating TNF-alpha associated disorders

#920

20140086930

2014-03-27

Formulation of human antibodies for treating TNF-α associated disorders

#921

20140086929

2014-03-27

Formulation of human antibodies for treating TNF-alpha associated disorders

#922

20140081000

2014-03-20

Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase

#923

20140072559

2014-03-13

Highly concentrated aqueous protein solution with reduced viscosity

#924

20140065159

2014-03-06

Antibody and protein formulations

#925

20140065158

2014-03-06

Anti-prolactin receptor antibody formulations

#926

20140065145

2014-03-06

Method for producing solid formulations comprising immunoglobulin single variable domains

#927

20140056877

2014-02-27

Stabilized liquid anti-RSV antibody formulations

#928

20140044717

2014-02-13

Methods of producing lyophilized polypeptide composition formulations comprising volatile additives

#929

20140044708

2014-02-13

Process for lowering the viscosity of highly concentrated protein solutions

#930

20140030252

2014-01-30

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

#931

20140017256

2014-01-16

Crystalline anti-human IL-12 antibodies

#932

20140004106

2014-01-02

Stable IgG4 based binding agent formulations

#933

20130344088

2013-12-26

Anti-BAFFR antibody formulation

#934

20130344085

2013-12-26

Anti-PCSK9 antibodies, formulations, dosing, and methods of use

#935

20130344084

2013-12-26

Cell culture methods to reduce acidic species

#936

20130338344

2013-12-19

Low acidic species compositions

#937

20130336968

2013-12-19

Pharmaceutical formulation comprising a biopharmaceutical drug

#938

20130330354

2013-12-12

Stabilized liquid egg material for extended shelf life

#939

20130330351

2013-12-12

Antibody and methods for selective inhibition of T-cell responses

#940

20130323267

2013-12-05

Highly concentrated anti-CD40 antibody pharmaceutical preparation

#941

20130323260

2013-12-05

Stabilized formulations containing anti-DLL4 antibodies

#942

20130317457

2013-11-28

Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition

#943

20130309699

2013-11-21

Antibody purification via affinity chromatography

#944

20130280248

2013-10-24

Method of stabilizing antibody and stabilized solution-type antibody preparation

#945

20130273066

2013-10-17

Self-buffering antibody formulations

#946

20130237690

2013-09-12

STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA

#947

20130224213

2013-08-29

Compositions and methods for stabilizing protein-containing formulations

#948

20130224185

2013-08-29

Protein formulation

#949

20130224183

2013-08-29

Fraction I-IV-1 precipitation of immunoglobins from plasma

#950

20130216556

2013-08-22

Antibody formulations

#951

20130216522

2013-08-22

STABILIZED HUMAN IMMUNOGLOBULIN COMPOSITION

#952

20130209465

2013-08-15

Stabilized Aqueous Antibody Compositions

#953

20130202620

2013-08-08

High concentration antibody formulations

#954

20130202585

2013-08-08

Method for stabilising an immunoglobulin G composition in liquid form

#955

20130197197

2013-08-01

Chromatographic method for purifying FC-containing proteins

#956

20130186797

2013-07-25

Stabilized formulations containing anti-Ang2 antibodies

#957

20130164296

2013-06-27

Excipients for Stabilising Viral Particles, Polypeptides or Biological Material

#958

20130156760

2013-06-20

Protein formulations and methods of making same

#959

20130136733

2013-05-30

Stable Multi-Dose Compositions Comprising an Antibody and a Preservative

#960

20130121991

2013-05-16

Concentrated human immunoglobulin composition

#961

20130108634

2013-05-02

Etanercept formulations stabilized with meglumine

#962

20130108633

2013-05-02

Etanercept formulations stabilized with metal ions

#963

20130108632

2013-05-02

Etanercept formulations stabilized with amino acids

#964

20130102760

2013-04-25

Immunoglobulin preparations having increased stability

#965

20130101640

2013-04-25

Etanercept formulations stabilized with combinations of sugars and polyols

#966

20130101584

2013-04-25

Etanercept formulations stabilized with xylitol

#967

20130101583

2013-04-25

Etanercept formulations stabilized with sodium chloride

#968

20130078232

2013-03-28

Compositions and methods useful for stabilizing protein-containing formulations

#969

20130071387

2013-03-21

Pharmaceutical formulations

#970

20130071384

2013-03-21

Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody

#971

20130058962

2013-03-07

Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein

#972

20130058958

2013-03-07

COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS

#973

20130052209

2013-02-28

PROTEIN DRUG FORMULATIONS AND PACKAGES

#974

20130052208

2013-02-28

Process for preparing an immunoglobulin composition

#975

20130045199

2013-02-21

Antibody preparations

#976

20130034551

2013-02-07

Wnt antagonists and methods of treatment and screening

#977

20130028907

2013-01-31

Stable antibody containing compositions

#978

20130028903

2013-01-31

PURIFIED ANTIBODY COMPOSITION

#979

20130022625

2013-01-24

Stabilized antibody-containing liquid formulations

#980

20130022621

2013-01-24

IL-17 receptor antibody formulation

#981

20130017598

2013-01-17

Prevention of disulfide bond reduction during recombinant production of polypeptides

#982

20130017197

2013-01-17

STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF

#983

20130017193

2013-01-17

Methods of treating inflammatory disorders using high concentration natalizumab compositions

#984

20130017191

2013-01-17

Immunoglobulin preparation and storage system for an immunoglobulin preparation

#985

20130012916

2013-01-10

DELIVERY OF IMMUNOGLOBULIN VARIABLE DOMAINS AND CONSTRUCTS THEREOF

#986

20130011388

2013-01-10

Intravenous immunoglobulin composition

#987

20130004484

2013-01-03

ANTI-C-MET ANTIBODY FORMULATIONS

#988

20120328614

2012-12-27

Immunoglobulin formulation and method of preparation thereof

#989

20120321638

2012-12-20

FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN

#990

20120321616

2012-12-20

Stabilized liquid anti-RSV antibody formulations

#991

20120321553

2012-12-20

Ultrafiltration concentration of allotype selected antibodies for small-volume administration

#992

20120315285

2012-12-13

Antibody formulation

#993

20120308514

2012-12-06

Human antibodies that bind human interleukin-12

#994

20120294847

2012-11-22

Immunoglobulin reduced in thrombogenic agents and preparation thereof

#995

20120282464

2012-11-08

Spherical Protein Particles and Methods of Making and Using Them

#996

20120282270

2012-11-08

Formulation of human antibodies for treating TNF-α associated disorders

#997

20120282249

2012-11-08

FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY

#998

20120264915

2012-10-18

Chromatography purification of antibodies

#999

20120263731

2012-10-18

High concentration anti-TNFα antibody liquid formulations

#1000

20120251566

2012-10-04

Saponin adjuvant compositions and methods relating thereto

#1001

20120244168

2012-09-27

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

#1002

20120244158

2012-09-27

STABLE FORMULATIONS OF POLYPEPTIDES AND USES THEREOF

#1003

20120238730

2012-09-20

INTEGRATED APPROACH TO THE ISOLATION AND PURIFICATION OF ANTIBODIES

#1004

20120237532

2012-09-20

PHARMACEUTICAL FORMULATION CONTAINING IMMUNOGLOBULIN

#1005

20120231009

2012-09-13

Formulations of Antibody

#1006

20120230982

2012-09-13

High concentration formulations of anti-C5 antibodies

#1007

20120225072

2012-09-06

STABLE FORMULATIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF

#1008

20120213792

2012-08-23

Methods of treatment using human antibodies that bind IL-12

#1009

20120201812

2012-08-09

Stable formulations of polypeptides and uses thereof

#1010

20120195897

2012-08-02

Human domain antibodies against components of the human insulin-like growth factor (IGF) system

#1011

20120195879

2012-08-02

Carrier immunoglobulins

#1012

20120183531

2012-07-19

Methods for Inhibiting Yellow Color Formation in a Composition

#1013

20120178683

2012-07-12

Stable liquid VEGF antagonist formulations

#1014

20120177704

2012-07-12

Crystalline anti-human IL-12 antibodies

#1015

20120148576

2012-06-14

HUMANIZED ANTI-CD 19 ANTIBODY FORMULATIONS

#1016

20120148568

2012-06-14

Variant immunoglobulins with improved manufacturability

#1017

20120134989

2012-05-31

ANTIBODY FORMULATIONS

#1018

20120128687

2012-05-24

NOVEL ANTIBODY FORMULATION

#1019

20120121591

2012-05-17

SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3

#1020

20120121581

2012-05-17

Anti-botulism antibody coformulations

#1021

20120121580

2012-05-17

METHODS FOR PRODUCING HIGH CONCENTRATION LYOPHILIZED PHARMACEUTICAL FORMULATIONS

#1022

20120121578

2012-05-17

METHODS OF USING IMMUNOGLOBULIN AGGREGATES

#1023

20120116057

2012-05-10

Stable and aggregation free antibody FC molecules through CH3 domain interface engineering

#1024

20120114646

2012-05-10

LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS

#1025

20120101035

2012-04-26

Dimer VEGF antagonist formulations

#1026

20120097565

2012-04-26

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

#1027

20120076800

2012-03-29

Non-aqueous high concentration reduced viscosity suspension formulations of antibodies

#1028

20120076783

2012-03-29

Reduced-viscosity concentrated protein formulations

#1029

20120076779

2012-03-29

STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph

#1030

20120076772

2012-03-29

Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH

#1031

20120064086

2012-03-15

High concentration antibody and protein formulations

#1032

20120045456

2012-02-23

STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS

#1033

20120041070

2012-02-16

METHODS OF TREATING CANCER HAVING AN ABERRANT EGFR OR KRAS GENOTYPE

#1034

20120039876

2012-02-16

Stabilized liquid anti-RSV antibody formulations

#1035

20120028877

2012-02-02

Self-Buffering Protein Formulations

#1036

20120027772

2012-02-02

THERAPEUTIC PROTEIN FORMULATIONS

#1037

20120022239

2012-01-26

PRECIPITATION OF BIOMOLECULES WITH NEGATIVELY CHARGED POLYMERS

#1038

20120009199

2012-01-12

Antibody formulations

#1039

20120003211

2012-01-05

Immunoglobulins with reduced aggregation

#1040

20110318343

2011-12-29

Stable aqueous pharmaceutical formulations of daclizumab antibodies

#1041

20110318332

2011-12-29

IMMUNOGLOBULIN G COMPOSITION

#1042

20110311556

2011-12-22

Anti-rhesus D monoclonal antibody

#1043

20110305695

2011-12-15

Wnt Antagonists and Methods of Treatment and Screening

#1044

20110262992

2011-10-27

METHOD FOR STABILIZING LABELED ANTIBODY

#1045

20110257370

2011-10-20

Immunoglobulin purification

#1046

20110256149

2011-10-20

ANTIBODY FORMULATION

#1047

20110256135

2011-10-20

ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY COMPOSITIONS

#1048

20110250195

2011-10-13

Antibodies against IL-25

#1049

20110236398

2011-09-29

Antibody Formulation

#1050

20110236391

2011-09-29

METHOD FOR OBTAINING AN EXCIPIENT-FREE ANTIBODY SOLUTION

#1051

20110236383

2011-09-29

Protein Formulation

#1052

20110229490

2011-09-22

Lyophilized formulations of engineered anti-IL-23p19 antibodies

#1053

20110226650

2011-09-22

ANTIBODY FORMULATION

#1054

20110223156

2011-09-15

REVERSIBLE GEL PROTEIN FORMULATION

#1055

20110212127

2011-09-01

Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine

#1056

20110201785

2011-08-18

METHOD FOR OPTIMIZING PROTEINS HAVING THE FOLDING PATTERN OF IMMUNOGLOBULIN

#1057

20110183861

2011-07-28

METHODS TO STABILIZE PROTEINS AND POLYPEPTIDES

#1058

20110177068

2011-07-21

PHARMACEUTICAL PREPARATION COMPRISING AN ANTIBODY AGAINST THE EGF RECEPTOR

#1059

20110171217

2011-07-14

Stable liquid antibody formulation

#1060

20110171176

2011-07-14

Complement antagonists and uses thereof

#1061

20110159002

2011-06-30

Stabilized liquid egg material for extended shelf life

#1062

20110158987

2011-06-30

NOVEL ANTIBODY FORMULATION

#1063

20110144311

2011-06-16

METHODS FOR PURIFYING ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY

#1064

20110130544

2011-06-02

ANTIBODIES WITH DECREASED DEAMIDATION PROFILES

#1065

20110129474

2011-06-02

Methods and systems for multi-antibody therapies

#1066

20110086038

2011-04-14

Methods of purifying anti-interleukin-13 antibodies

#1067

20110076722

2011-03-31

Stable multivalent antibody

#1068

20110076275

2011-03-31

Method of modifying isoelectric point of antibody via amino acid substitution in CDR

#1069

20110070231

2011-03-24

STABLE LIQUID PHARMACEUTICAL FORMULATION OF IGG ANTIBODIES

#1070

20110070225

2011-03-24

Beta antibody parenteral formulation

#1071

20110066111

2011-03-17

Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof

#1072

20110059079

2011-03-10

Antibody Coformulations

#1073

20110046353

2011-02-24

Purification Process for Anitbody Fragments Using Derivatized Triazines as Affinity Ligands

#1074

20110044998

2011-02-24

Stabilized angiopoietin-2 antibodies and uses thereof

#1075

20110044990

2011-02-24

ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES

#1076

20110044977

2011-02-24

Subcutaneous anti-HER2 antibody formulations and uses thereof

#1077

20110033549

2011-02-10

Stabilisation of Proteins

#1078

20110027292

2011-02-03

Protein Formulations with Reduced Viscosity and Uses Thereof

#1079

20110027272

2011-02-03

Stabilized liquid anti-RSV antibody formulations

#1080

20110027262

2011-02-03

PLATFORM ANTIBODY COMPOSITIONS

#1081

20110020328

2011-01-27

ANTIBODY FORMULATIONS

#1082

20110014676

2011-01-20

PROTEIN STABILIZATION

#1083

20110014189

2011-01-20

Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents

#1084

20110008362

2011-01-13

Anti-gluten egg yolk antibodies for the treatment of celiac disease

#1085

20110003972

2011-01-06

STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA

#1086

20110002935

2011-01-06

Purified antibody composition

#1087

20100330099

2010-12-30

Stabilized anti-hepatitis B (HBV) antibody formulations

#1088

20100330071

2010-12-30

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

#1089

20100316638

2010-12-16

Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs

#1090

20100316593

2010-12-16

Pharmaceutical formulations

#1091

20100310548

2010-12-09

Methods of Manufacturing a Biologic Using a Stable Storage Intermediate

#1092

20100303879

2010-12-02

Silane-functionalized hydrophobic α(1→4)glucopyranose polymers and polymeric matrices for implantation or injection

#1093

20100303878

2010-12-02

BIODEGRADABLE BIOACTIVE AGENT RELEASING MATRICES WITH PARTICULATES

#1094

20100303827

2010-12-02

Protein formulation

#1095

20100303736

2010-12-02

ANTI-IL-9 ANTIBODY FORMULATIONS AND USES THEREOF

#1096

20100297117

2010-11-25

Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration

#1097

20100292092

2010-11-18

ANTIBODY FORMULATIONS

#1098

20100285011

2010-11-11

High concentration antibody-containing liquid formulation

#1099

20100279933

2010-11-04

VEGF antagonist formulations

#1100

20100278830

2010-11-04

Methods and systems for multi-antibody therapies

#1101

20100278822

2010-11-04

STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES

#1102

20100273991

2010-10-28

Method of covalently modifying proteins with organic molecules to prevent aggregation

#1103

20100260766

2010-10-14

STABLE ANTIBODY FORMULATIONS

#1104

20100260751

2010-10-14

Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases

#1105

20100254985

2010-10-07

Protein Formulations

#1106

20100239567

2010-09-23

Anti-oxidized LDL antibody formulation

#1107

20100209437

2010-08-19

Anti-CD3 Antibody Fromulations

#1108

20100209434

2010-08-19

ANTIBODY FORMULATION

#1109

20100189721

2010-07-29

ANTIBODY FORMULATIONS

#1110

20100172862

2010-07-08

STABLE ANTIBODY COMPOSITIONS AND METHODS OF STABILIZING SAME

#1111

20100166752

2010-07-01

Anti A beta antibody formulation

#1112

20100158925

2010-06-24

Lyophilized formulations of anti-egfr antibodies

#1113

20100158919

2010-06-24

Pharmaceutical Composition

#1114

20100158908

2010-06-24

Stable polypeptide formulations

#1115

20100158899

2010-06-24

PROTEIN FORMULATION

#1116

20100158898

2010-06-24

METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS

#1117

20100151247

2010-06-17

Precipitation stabilising compositions comprising bioactive molecule and at least one cationic and one anionic precipitation stabilizing additives

#1118

20100137213

2010-06-03

Formulations of single domain antigen binding molecules

#1119

20100129379

2010-05-27

STABILIZED ANTIBODY FORMULATIONS AND USES THEREOF

#1120

20100105873

2010-04-29

Integrated approach for generating multidomain protein therapeutics

#1121

20100098700

2010-04-22

Pharmaceutical compositions for binding sphingosine-1-phosphate

#1122

20100074903

2010-03-25

NOVEL ANTIBODY FORMULATION

#1123

20100068210

2010-03-18

COMPOSITIONS AND METHODS FOR THE PREVENTION OF OXIDATIVE DEGRADATION OF PROTEINS

#1124

20100055097

2010-03-04

Stable lyophilized pharmaceutical formulation of IgG antibodies

#1125

20100034829

2010-02-11

Liquid anti-rabies antibody formulations

#1126

20100028372

2010-02-04

STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS

#1127

20100021461

2010-01-28

Immunoglobulin formulation and method of preparation thereof

#1128

20100015157

2010-01-21

Antibody formulations

#1129

20090311251

2009-12-17

scFv antibodies which pass epithelial and/or endothelial layers

#1130

20090306348

2009-12-10

Antibody Formulation

#1131

20090297533

2009-12-03

Controlled release immunomodulator compositions and methods for the treatment of otic disorders

#1132

20090292109

2009-11-26

Method of Isolating Biomacromolecules Using Polyalkylene Glycol and Transition Metals

#1133

20090291076

2009-11-26

Stabilized antibody-containing formulations

#1134

20090291062

2009-11-26

Antibody formulations and methods of making same

#1135

20090285802

2009-11-19

Highly concentrated stabilized IgM solution

#1136

20090280129

2009-11-12

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

#1137

20090270596

2009-10-29

Chromatography purification of antibodies

#1138

20090269359

2009-10-29

Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM

#1139

20090269302

2009-10-29

HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING

#1140

20090264629

2009-10-22

Stabilized protein-containing formulations

#1141

20090238820

2009-09-24

ANTI-MAdCAM ANTIBODY COMPOSITIONS

#1142

20090226530

2009-09-10

Powdered protein compositions and methods of making same

#1143

20090214535

2009-08-27

Pharmaceutical compositions containing sc(Fv)2

#1144

20090214522

2009-08-27

PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF

#1145

20090208492

2009-08-20

Lyophilized Immunoglobulin Formulations and Methods of Preparation

#1146

20090202039

2009-08-13

Methods for sterilizing biological materials containing non-aqueous solvents

#1147

20090176220

2009-07-09

ANTIBODY CHARACTERIZATION TEST

#1148

20090175883

2009-07-09

Stabilized anti-respiratory syncytial virus (RSV) antibody formulations

#1149

20090175857

2009-07-09

Human Antibodies That Bind Human IL-12 And Methods For Producing

#1150

20090171072

2009-07-02

Process for preparing unaggregated antibody Fc domains

#1151

20090162352

2009-06-25

ANTIBODY FORMULATION

#1152

20090148521

2009-06-11

Solid oral form of a medicinal preparation and a method for the production thereof

#1153

20090131639

2009-05-21

Antibody-containing solution formulations

#1154

20090130119

2009-05-21

Anti-CTLA-4 antibody compositions

#1155

20090117097

2009-05-07

Stabilizer for protein preparation comprising meglumine and use thereof

#1156

20090110681

2009-04-30

Anti-M-CSF Antibody Compositions

#1157

20090068196

2009-03-12

Pharmaceutical formulation of an antibody against IL13Ralpha1

#1158

20090060906

2009-03-05

Anti-IL-13 antibody formulations and uses thereof

#1159

20090053786

2009-02-26

Prevention of disulfide bond reduction during recombinant production of polypeptides

#1160

20090042315

2009-02-12

Compositions of specific binding agents to hepatocyte growth factor

#1161

20080311119

2008-12-18

ANTIBODY FORMULATIONS

#1162

20080311078

2008-12-18

Self-Buffering Protein Formulations

#1163

20080306247

2008-12-11

Antibody-containing solution formulations

#1164

20080305114

2008-12-11

HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING

#1165

20080292642

2008-11-27

Crystalline anti-human IL-12 antibodies

#1166

20080286280

2008-11-20

Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies

#1167

20080286270

2008-11-20

Stabilized liquid anti-RSV antibody formulations

#1168

20080275220

2008-11-06

Method for stabilizing a protein

#1169

20080274101

2008-11-06

STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA

#1170

20080254132

2008-10-16

High pressure spray-dry of bioactive materials

#1171

20080248048

2008-10-09

Interleukin-13 Antibody Composition

#1172

20080248047

2008-10-09

Platform Antibody Compositions

#1173

20080206242

2008-08-28

METHOD OF TREATMENT OF TH2-MEDIATED CONDITIONS USING OPTIMIZED ANTI-CD30 ANTIBODIES

#1174

20080200656

2008-08-21

Use Of Sucrose To Suppress Mannitol-Induced Protein Aggregation

#1175

20080200655

2008-08-21

Protein Formulations Containing Sorbitol

#1176

20080187568

2008-08-07

Polymerization with precipitation of proteins for elution in physiological solution

#1177

20080160014

2008-07-03

Protein formulations with reduced viscosity and uses thereof

#1178

20080154023

2008-06-26

Methods and compositions with reduced opalescence

#1179

20080152658

2008-06-26

Stabilized anti-hepatitis B (HBV) antibody formulations

#1180

20080139792

2008-06-12

High Protein Concentration Formulations Containing Mannitol

#1181

20080124326

2008-05-29

Stable polypeptide formulations

#1182

20080112953

2008-05-15

Stable formulations

#1183

20080089898

2008-04-17

Immunotoxins directed against CD33 related surface antigens

#1184

20080071063

2008-03-20

Protein Formulations

#1185

20080064856

2008-03-13

Methods for reducing protein aggregation

#1186

20080063635

2008-03-13

Stabilized human Igg4 antibodies

#1187

20080050364

2008-02-28

Treatment of LFA-1 Associated Disorders with Increasing Doses of LFA-1 Antagonist

#1188

20080003220

2008-01-03

Buffering agents for biopharmaceutical formulations

#1189

20070292442

2007-12-20

Antibody purification

#1190

20070280933

2007-12-06

Methods for decreasing immune response and treating immune conditions

#1191

20070237762

2007-10-11

Process for Concentration of Antibodies and Therapeutic Products Thereof

#1192

20070212346

2007-09-13

Highly Concentrated Stabilized Igm Solution

#1193

20070172479

2007-07-26

Protein formulations with reduced viscosity and uses thereof

#1194

20070166309

2007-07-19

OPTIMIZED ANTI-CD30 ANTIBODIES

#1195

20070148171

2007-06-28

Optimized anti-CD30 antibodies

#1196

20070122411

2007-05-31

Solid forms of anti-EGFR antibodies

#1197

20070122402

2007-05-31

Immunoglobulin preparations having increased stability

#1198

20070116700

2007-05-24

Reduced-viscosity concentrated protein formulations

#1199

20070086995

2007-04-19

Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations

#1200

20070071750

2007-03-29

Human antibodies that specifically recognize the toxin Cn2 from scorpion venom